Press Releases September 8, 2026 07:30 AM

OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

OptimizeRx to present at the 10th Annual Lake Street Best Ideas Growth Conference

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
OPRX

OptimizeRx Corp., a healthcare technology company specializing in AI-driven engagement platforms for life sciences brands, announced its participation in the upcoming Lake Street Capital Best Ideas Growth Conference. The event provides an opportunity for management to connect with investors and showcase their innovative healthcare marketing solutions.

OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
OPRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OptimizeRx is showcasing its healthcare technology platform at a prominent growth conference to attract investor interest.
  • The company uses AI-driven tools like Dynamic Audience Activation Platform and Micro-Neighborhood Targeting to connect life science brands with healthcare providers and patients.
  • Participation highlights OptimizeRx's goal to expand visibility within the healthcare technology and life sciences sectors, emphasizing synchronized marketing solutions that can improve patient outcomes.

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced that management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 10, 2026, in New York, NY.

To request a meeting or for more details about the conferences please reach out to your institutional contact.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting® (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X,  LinkedIn  or visit www.optimizerx.com.  

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
adsilva@optimizerx.com

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com


Risks

  • Market response to the conference presentation is uncertain and may not translate into immediate stock price appreciation.
  • The company's growth depends on continued adoption of its AI-driven solutions by the pharmaceutical and healthcare sectors, which can be impacted by regulatory changes or competitive technologies.
  • Privacy and data security remain critical in healthcare technology; any shortcomings could affect company reputation and partnerships.

More from Press Releases

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars Sep 8, 2026 Worthington Enterprises Schedules Fiscal First Quarter 2027 Earnings Call for September 23 Sep 8, 2026 FTC Solar Begins Shipments on 330 MW Fraser Coast Project in Australia Sep 8, 2026 Upexi to Participate in FT Partners FinTech Conference 2026 on September 15th Sep 8, 2026 Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations Sep 8, 2026